

BMJ Open Annual FEV₁ changes and numbers of circulating endothelial microparticles in patients with COPD: a prospective study

Toru Takahashi,^{1,2,3} Seiichi Kobayashi,⁴ Naoya Fujino,¹ Takaya Suzuki,⁵ Chiharu Ota,¹ Yukiko Tando,¹ Mitsuhiro Yamada,⁶ Masaru Yanai,⁴ Mutsuo Yamaya,¹ Shin Kurosawa,² Masanori Yamauchi,² Hiroshi Kubo¹

To cite: Takahashi T, Kobayashi S, Fujino N, *et al*. Annual FEV₁ changes and numbers of circulating endothelial microparticles in patients with COPD: a prospective study. *BMJ Open* 2014;**4**:e004571. doi:10.1136/bmjopen-2013-004571

► Additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/bmjopen-2013-004571>).

Received 28 November 2013
Revised 5 February 2014
Accepted 17 February 2014



CrossMark

For numbered affiliations see end of article.

Correspondence to

Dr Hiroshi Kubo;
hkubo@med.tohoku.ac.jp

ABSTRACT

Objective: Growing evidence suggests that endothelial injury is involved in the pathophysiology of chronic obstructive pulmonary disease (COPD). Circulating endothelial microparticles (EMPs) increase in patients with COPD because of the presence of endothelial injury. We examined the relationship between EMP number and changes in forced expiratory volume in 1 s (FEV₁) in patients with COPD.

Design: Prospective study.

Setting: One hospital in Japan.

Participants: A total 48 outpatients with stable COPD coming to the hospital from September 2010 to September 2011.

Primary and secondary outcomes measured:

Blood samples were collected and vascular endothelial (VE)-cadherin EMPs (CD144+ EMPs), E-selectin EMPs (CD62E+ EMPs) and platelet endothelial cell adhesion molecule EMPs (CD31+/CD41– EMPs) were measured using fluorescence-activated cell sorting. Annual FEV₁ changes were evaluated using FEV₁ data acquired a year before and a year after sample collection.

Results: The number of E-selectin and VE-cadherin EMPs showed significant negative correlations with annual FEV₁ changes ($r_s = -0.65$, $p < 0.001$, $r_s = -0.43$, $p = 0.003$, respectively). Leucocyte counts tended to be correlated with annual FEV₁ changes, but this correlation was not significant ($r_s = -0.28$, $p = 0.057$). There were significant differences in annual FEV₁ changes between with and without history of frequent exacerbation ($p = 0.006$), and among Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages ($p = 0.009$). Multiple linear regression analysis revealed E-selectin EMP to be the only significant parameter associated with annual FEV₁ changes, independent of VE-cadherin EMP, GOLD stages, leucocyte counts, and history of frequent exacerbation. Receiver operating characteristic curves showed the optimum E-selectin EMP cut-off level for prediction of rapid FEV₁ decline (>66 mL/year) to be 153.0/μL (areas under curve 0.78 (95% CI 0.60 to 0.89); sensitivity, 67%; specificity, 81%).

Conclusions: The high E-selectin EMP levels in stable patients with COPD are predictive of rapid FEV₁ decline.

Trial registration number: UMIN000005168.

Strengths and limitations of this study

- This is a prospective observational study investigating the relationship between endothelial microparticle (EMP) numbers and annual forced expiratory volume in 1 s (FEV₁) changes in chronic obstructive pulmonary disease (COPD) patients.
- High E-selectin EMP levels in stable condition predict rapid FEV₁ decline independent of vascular endothelial (VE)-cadherin EMPs, GOLD stages, leucocyte counts, and history of frequent exacerbation.
- A relatively small number of patients from a single institution.
- We could not exclude influence of reduced pulmonary capillary bed in advanced COPD lungs on circulating EMP numbers.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a lung condition defined by airflow limitation. The severity of COPD is determined by the degree of airflow limitation, and disease progression is evaluated by a decline in forced expiratory volume in 1 s (FEV₁). However, FEV₁ decline is not a good parameter to judge COPD progression in the short term. Therefore, new biomarkers to evaluate disease activity and heterogeneity are needed.¹ Growing evidence suggests that endothelial inflammation is closely involved in the pathophysiology of COPD. Endothelial impairment in the systemic vasculature, evaluated by flow-mediated dilation of the brachial artery, was reported to be associated with lower FEV₁ values.² Furthermore, the incidence of premature death due to cardiovascular diseases was found to be high in patients with decreased FEV₁.³ Severe endothelial inflammation exists in patients with

COPD with a history of frequent exacerbation, even during the stable phase,⁴ and frequent exacerbation is a well-known factor associated with rapid FEV₁ decline.^{5–8} Therefore, we speculated that the evaluation of endothelial impairment may enable the prediction of COPD progression.

Circulating endothelial microparticles (EMPs) are shed membrane vesicles released from activated or apoptotic endothelial cells when these cells are injured.^{9–10} The number of EMPs was found to be significantly increased in patients with vascular disorders such as coronary heart disease,¹¹ stroke,¹² renal failure¹³ and hyperlipidaemia¹⁴ as well as in current smokers.¹⁵ These EMPs are recognised markers of endothelial damage and are defined according to endothelial-specific antigens on their membranes, such as CD144 EMPs (vascular endothelial (VE)-cadherin EMPs), CD31/CD41 EMPs (platelet endothelial cell adhesion molecule (PECAM) EMPs) and CD62E EMPs (E-selectin EMPs). Differences among these released EMP subtypes have been observed in patients with various diseases such as pulmonary hypertension and acute coronary syndrome^{16–17} during COPD exacerbation,⁴ and they reflect differences in the condition of injured endothelial cells or types of inflammation.^{18–19}

We previously reported that, compared with healthy controls, the numbers of EMPs, mainly released from pulmonary capillary vasculatures, was significantly increased in patients with stable COPD, while it was further increased in patients with exacerbated COPD.⁴ In addition, Thomashow *et al*²⁰ (the MESA group) also reported significant correlations between EMP number and the degree of lung destruction and emphysematous changes in patients with mild-to-moderate COPD and those without. Furthermore, apoptosis of pulmonary capillary endothelial cells was reported to lead to emphysematous changes in animal model.²¹ However, a relationship between elevated EMP numbers and COPD progression has not been clarified. Therefore, we hypothesised that high EMP levels predicted rapid FEV₁ decline and conducted this prospective study to determine the correlation between EMP number and annual FEV₁ changes in patients with COPD.

Some of the results from this study have been previously presented in an Abstract.²²

METHODS

Patient population

This was a prospective observational study investigating the relationship between EMP number and annual FEV₁ changes in patients with COPD. The study protocol is summarised in figure 1. All participants provided written informed consent.

Airflow limitation was determined by spirometry and defined as a postbronchodilator FEV₁/forced vital capacity (FVC) of <0.70. Severity was classified in accordance with the Global Initiative for Chronic Obstructive Lung Disease

(GOLD) criteria.²³ We defined stable patients with COPD as those without episode of exacerbation within 3 months prior to sample collection. We excluded participants with history of cardiovascular events such as acute coronary syndrome and acute stroke within the past year prior to sample collection, to exclude influences of these cardiovascular events on the EMP levels in stable patients with COPD.^{11–12} In addition, we excluded those with renal failure,¹³ diabetes mellitus,²⁴ hyperlipidaemia¹⁴ and thromboembolic disease²⁵ because these diseases reportedly influence EMP number. Current smokers were also excluded because the EMP number is reportedly increased in current smokers compared with that in never smokers.¹⁵ We excluded patients who had undergone lung resection because lung resection itself may influence annual FEV₁ changes. Patients with COPD with other respiratory diseases such as asthma and interstitial pneumonia were also excluded. No patients had medication of statin. Among 381 patients with COPD who visited at the Japanese Ishinomaki Red Cross Hospital from September 2010 to September 2011, a total of 82 outpatients with stable COPD, including 53 patients enrolled in the former study published in *Thorax* 2012,⁴ at the Japanese Ishinomaki Red Cross Hospital were eligible to participate in the EMP study. Of these, 17 were excluded because of missing spirometric data before blood sample collection or EMP data, leaving 65 stable patients with COPD enrolled in this prospective study investigating EMP number and annual FEV₁ changes. Blood samples and spirometry data were collected from all participants. After a year of observation, spirometry was repeated. An additional 17 patients were excluded during the observation period, leaving 48 that completed the study. No patient changed drug treatment 2 years before sample collection or during the observation period.


Blood sampling

Peripheral venous blood was collected into heparinised tubes. Blood samples were centrifuged for 10 min at 170 g, and plasma was then harvested and centrifuged for 20 min at 1500 g to obtain platelet-free plasma (PFP) as previously described.²⁶

Characterisation of EMPs

EMP subpopulations were determined by flow cytometry in PFP according to the expression of membrane-specific antigens. Three EMP subtypes were defined as follows: CD144 (FITC) MPs (VE-cadherin EMPs), CD31 (FITC)/CD41 (PE) MPs (PECAM EMPs) and CD62E (PE) MPs (E-selectin EMPs). PFP (10 µL) was incubated with each specific antibody (see online supplementary table E1) for 30 min at room temperature. Samples were then diluted in 300 µL of a 0.9% saline salt solution. Equal volumes of sample and Flowcount beads (Beckman–Coulter) were then added and analysed using fluorescence-activated cell sorting (FACS). We made a microparticle gate to include events <1 µm in an FSC-SSC scattergram using 1 µm beads (Fluka, Sigma). Appropriate isotype control

Figure 1 Flowchart of patient enrolment and reasons for exclusion. COPD, chronic obstructive pulmonary disease; EMP, circulating endothelial microparticle; FACS; fluorescence-activated cell sorting; FEV₁, forced expiratory volume in 1 s.



antibodies were used to increase the specificity of MP detection. The EMP numbers were calculated as absolute numbers of EMPs per μL PFP.

Pulmonary function tests

Spirometry measurements were conducted by a well-trained technician following the American Thoracic Society and European Respiratory Society guidelines after participants inhaled a bronchodilator prior to sample collection.²⁷ Acceptable manoeuvres for spirometry measurements were defined as those with a sufficient peak expiratory flow, a rapid start, an absence of major flow fluctuations and an adequate duration of expiration. Pulmonary function testing was performed in duplicate, and the best FEV₁ and FVC values were recorded from acceptable manoeuvres.²⁸

Calculation of annual FEV₁ changes

Annual FEV₁ changes at sample collection were evaluated using FEV₁ data obtained a year before sample collection, at sample collection and a year after sample collection. FEV₁ data for each patient over 2 years were plotted on FEV₁ versus year scattergrams. To evaluate annual FEV₁ change, regression coefficients (mL/year) were calculated using JMP V.9 statistical analysis software (SAS Institute, Cary, North Carolina, USA).

Severity of emphysema evaluated by the Goddard classification

We visually evaluated the severity of emphysema according to the modified Goddard classification as previously described.²⁹ We used a high-resolution chest CT to quantify low attenuation areas (LAAs). LAA was scored for the right and left sides of the upper, middle and lower lung fields. Zero represented no abnormality, while 1 was given for up to 25%, 2 for up to 50%, 3 for up to 75% and 4 for almost the total absence of normal lung tissue. The total possible scores ranged from 0 to 24. The evaluation was independently performed by two pulmonologists in a blinded fashion, and the means of the two scores assigned by the two readers was calculated.

Statistical analysis

All data are presented as mean $\pm$ SD unless otherwise stated. Differences in annual FEV₁ changes between sexes, history of frequent exacerbation, use of inhaled or systemic corticosteroids and use of β agonists were analysed using the Mann-Whitney U test. The Kruskal-Wallis test was used to compare annual FEV₁ changes among the four GOLD stages. Correlations between annual FEV₁ changes and EMP number, age, body mass index, pack-years smoking index, leucocyte counts and C reactive protein were calculated using Spearman non-parametric methods.

Multivariate linear regression analysis was performed to evaluate the impact of VE-cadherin EMP number, E-selectin EMP number, GOLD stage and history of frequent exacerbation on annual FEV₁ changes. We evaluated sensitivity, specificity and respective areas under the curve (AUC) using receiver operating characteristic (ROC) curves. The optimum cut-off value of the E-selectin EMP number for prediction of rapid FEV₁ decline was calculated to maximise the sum of sensitivity and specificity by minimising the distance of the cut-off value to the top-left corner of the ROC curve. *p* Values of <0.05 were considered statistically significant. All analyses were performed using the JMP V.9.

RESULTS

Characteristics of subjects who completed the study

The characteristics of the 48 stable patients with COPD at sample collection are shown in table 1. Eight patients were classified as stage I, 16 as stage II, 13 as stage III and 11 as stage IV. We defined frequent exacerbation as two or more episodes of exacerbation every year according to the GOLD guideline.²³ LAA score ranged from 2 to 24 (median 16.5). There was significant correlation between LAA scores and FEV₁/FVC ratio ($r_s=-0.36$, $p=0.015$), FEV₁ ($r_s=-0.31$, $p=0.035$) or predicted FEV₁% ($r_s=-0.41$, $p=0.005$). A total of 22 patients had a history of frequent exacerbation. In the past year, prior to the sample collection, 46 episodes of exacerbation occurred in all 21 patients with history of frequent exacerbation, and there was no episode in patients without history of exacerbation. During 1-year follow-up period, 57 episodes occurred in 23 patients including of 21 patients

with history of frequent exacerbation. All patients had used anticholinergics, 35 had used inhaled or systemic corticosteroids and 25 had used β agonists.

Rate of annual FEV₁ changes

The mean rate of annual FEV₁ changes was -32.5 ± 51.5 mL/year, which was consistent with that reported in a previous study performed by Vestbo *et al*⁶ (-33 ± 52 mL/year). We defined patients with rapid FEV₁ decline as those in less than the 25th centile of annual FEV₁ changes. There were 12 patients with rapid FEV₁ decline, and annual FEV₁ changes ranged from -66.0 to -151.0 mL/year (median, -84.5 mL/year).

Effects of sex, GOLD stage, history of frequent exacerbation or use of drugs on annual FEV₁ changes (univariable analysis)

There was no significant difference in annual FEV₁ changes between men and women ($p=0.473$). In addition, there was no difference between patients who used steroids or β agonists and those who did not (steroids: $p=0.862$, β agonists: $p=0.861$). In contrast, there was a significant difference among GOLD stages ($p=0.009$). FEV₁ declined more rapidly in patients with frequent exacerbation than in those without ($p=0.006$; table 2 and figure 2).

Correlation between annual FEV₁ changes and EMP number or continuous variables of patient characteristics (univariable analysis)

There were significant negative correlations between annual FEV₁ changes and VE-cadherin EMP ($r_s=-0.43$, $p=0.003$) or E-selectin EMP number ($r_s=-0.65$, $p<0.001$). However, there was no significant correlation among annual FEV₁ changes and age, pack-years smoking index, leucocyte count or C reactive protein (table 3 and figure 3).

Independent parameters associated with annual FEV₁ changes (multiple linear regression analysis)

Following the results of univariate analysis, multivariate linear regression analysis was performed with annual

Table 1 Characteristics of the 48 stable patients with COPD at the time of enrolment in the study

Variables	
Age, years	73.3 $\pm$ 7.7
Gender, male/female	42/6
Body mass index, kg/m ²	22.3 $\pm$ 3.7
Lung function	
FEV ₁ , L	1.32 $\pm$ 0.58
FEV ₁ /FVC ratio (%)	46.8 $\pm$ 13.5
Predicted FEV ₁ (%)	56.4 $\pm$ 26.5
GOLD stage (I/II/III/IV)	8/16/13/11
LAA score (median $\pm$ IQR)	16.5 $\pm$ 11.0
History of frequent exacerbation (yes/no)	21/27
Pack-years smoking index (median $\pm$ IQR)	40.0 $\pm$ 38.8
Leucocyte count (/ μ L)	6848 $\pm$ 1832
C reactive protein	0.50 $\pm$ 1.62
Long-term oxygen therapy (yes/no)	8/40
Use of inhaled anticholinergic drugs (yes/no)	48/0
Use of inhaled corticosteroids (yes/no)	35/13
Use of long-acting β agonists (yes/no)	25/23

COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; LAA, low attenuation area.

Table 2 Effects of categorical variables on the annual FEV₁ changes in stable patients with COPD (univariable analysis)

Variables	<i>p</i> Value
Gender (male vs female)	0.473
History of frequent exacerbation (yes vs no)	0.006
GOLD stage (I/II/III/IV)	0.009
Long-term oxygen therapy (yes/no)	0.128
Use of inhaled corticosteroids (yes vs no)	0.862
Use of long-acting β agonists (yes vs no)	0.861

Bold typeface indicates statistical significance.

COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in 1 s; GOLD, Global Initiative for Chronic Obstructive Lung Disease.




Figure 2 Comparisons of annual forced expiratory volume in 1 s (FEV₁) changes (A) among Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages and (B) between patients with and without a history of frequent exacerbation.

FEV₁ decline as the dependent variable and VE-cadherin EMP number, E-selectin EMP number, GOLD stages and history of frequent exacerbation, and leucocyte counts as independent variables. Only E-selectin EMP number was identified as an independent parameter ($|r|=0.67$, $p<0.001$; table 4). In addition, E-selectin EMP number was an independent predictor for COPD exacerbation during the follow-up period (see online supplementary table E3).

ROC curve of E-selectin EMP number for the prediction of rapid FEV₁ decline

We assessed the association of E-selectin EMP number under a stable condition with rapid FEV₁ decline (≥ 66 mL/year) using AUC analysis. ROC curves showed that the optimum cut-off value of E-selectin EMP level for the prediction of rapid FEV₁ decline was 153.0/ μ L (AUC 0.78 (95% CI 0.60 to 0.89; sensitivity, 67%; specificity, 81%; figure 4).

Table 3 Effects of various continuous variables on annual FEV₁ changes in stable patients with COPD (univariable analysis)

Variables	r_s	p Value
EMPs		
VE-cadherin EMPs	-0.43	0.003
E-selectin EMPs	-0.65	<0.001
PECAM EMPs	0.03	0.834
Age	0.01	0.968
Body mass index	-0.01	0.943
LAA score	0.02	0.819
Pack-years smoking index	-0.002	0.988
Leucocyte counts	-0.28	0.057
C reactive protein	-0.03	0.838
Serum amyloid A	-0.15	0.365
D-dimer	-0.19	0.296

Bold typeface indicates statistical significance.

COPD, chronic obstructive pulmonary disease; EMPs, circulating endothelial microparticles; FEV₁, forced expiratory volume in 1 s; LAA, low attenuation area; PECAM, platelet endothelial cell adhesion molecule; VE-cadherin, vascular endothelial-cadherin.

DISCUSSION

In this study, we found that VE-cadherin and E-selectin EMP number under a stable condition had significant negative correlations with annual FEV₁ changes. In multiple linear regression analysis, only E-selectin EMP level under a stable condition was a significant factor associated with annual FEV₁ changes, while VE-cadherin EMP level, GOLD stage and a history of frequent exacerbation were not. The ROC curve showed that the optimum cut-off value of E-selectin EMP level for the prediction of rapid FEV₁ decline was 153.0/ μ L, with good sensitivity and specificity. From these results, we concluded that a high E-selectin EMP level under a stable condition predicted rapid FEV₁ decline after a year in patients with COPD. Therefore, the E-selectin EMP number under a stable condition could be a good biomarker to predict the prognosis of patients with COPD.

Elevated E-selectin EMP numbers may suggest the presence of endothelial inflammation, even under a stable condition. We previously reported that E-selectin EMP numbers increased during COPD exacerbation but decreased to below baseline levels after the patient's condition recovered,⁴ suggesting that elevated E-selectin EMP numbers can be modulated by medical treatments. Although a treatment that decreases E-selectin EMP numbers has not yet been established, maintaining that a low E-selectin EMP level may be a possible strategy to prevent the progression of lung destruction and/or airway obstruction in COPD.

Previous studies indicated that frequent exacerbation is reportedly associated with rapid FEV₁ decline⁵⁻⁸; however, a history of frequent exacerbation was not an independent factor for FEV₁ decline in this study. One reason to explain this discrepancy is that effects of frequent exacerbation on FEV₁ declines were weak when compared with other factors, such as smoking, and reportedly varied among studies due to differences in study design, sample size and inclusion criteria. In this study, E-selectin EMP level had a significant negative correlation with annual FEV₁ changes in those without ($r_s=-0.60$, $p=0.002$) and with a history of frequent




Figure 3 Correlations between annual FEV₁ changes and (A) VE-cadherin EMPs, (B) E-selectin EMPs and (C) PECAM EMPs. Filled circles indicate patients with a history of frequent exacerbation and open circles indicate patients without a history of frequent exacerbation. EMPs, circulating endothelial microparticles; FEV₁, forced expiratory volume in 1 s; PECAM, platelet endothelial cell adhesion molecule; PFP, platelet-free plasma; VE-cadherin, vascular endothelial-cadherin.

exacerbation ($r_s = -0.50$, $p = 0.027$). In addition, E-selectin EMPs have significant positive correlations with leucocyte counts and SAA (see online supplementary table E2). Patients with COPD with a history of frequent exacerbation demonstrate high E-selectin EMP numbers under stable conditions,⁴ suggesting the presence of higher endothelial inflammation. Recent reports indicated that EMP itself bound with circulating leucocytes, which induced further inflammation.³⁰ Therefore, we speculated that endothelial inflammation was a predominant factor for the rapid FEV₁ decline in patients with COPD. E-selectin EMPs can be released from both the systemic and the pulmonary vasculature. The high levels of E-selectin EMPs could be from the systemic inflammatory response present in COPD. However, increased EMP levels correlated with early lung destruction in smokers,¹⁵ suggesting EMP release from injured pulmonary capillary endothelium. Further study to identify the origin of E-selectin EMPs is necessary.

PECAM EMP number was reportedly associated with the percent emphysema on CT scans,²⁰ but it did not correlate with annual FEV₁ decline in this study. PECAM-1 is constitutively expressed on endothelial cells,

but E-selectin is rapidly expressed when endothelial cells are activated by inflammation.³¹ Therefore, the released E-selectin EMPs reflected the presence of endothelial inflammation. However, almost 90% PECAM EMPs in patients with COPD coexpressed annexin V,⁴ and released PECAM EMPs reflect apoptosis of endothelial cells.^{18 19} Therefore, elevated PECAM EMPs are the consequence of lung destruction with endothelial apoptosis, and endothelial inflammation with upregulated E-selectin expression dominantly plays a key role in prospective COPD progression.

A limitation of this study is that EMP number may change under certain conditions, particularly before the onset of clinical events and after treatments for the events. To clarify the relationship between changes in pulmonary function and EMP number, we excluded patients who suffered from exacerbations within 3 months after sample collection in this study. In addition, because the onset of cardiovascular diseases may

Table 4 Comparison of impact on annual FEV₁ changes among VE-cadherin EMP number, E-selectin EMP number, GOLD stage and history of frequent exacerbation (multiple linear regression analysis)

Parameter	Annual FEV ₁ changes per unit change in parameter	p Value
VE-cadherin EMPs	-0.0003	0.994
E-selectin EMPs	-0.32	<0.001
GOLD stage (I/II/III/IV)	-9.43	0.243
History of frequent exacerbations	-6.42	0.667
Leucocyte counts	-0.003	0.414

Bold typeface indicates statistical significance.

$|r| = 0.67$, $p < 0.001$.

EMPs, circulating endothelial microparticles; FEV₁, forced expiratory volume in 1 s; GOLD, Global Initiative for Chronic Obstructive Lung Disease; VE-cadherin, vascular endothelial-cadherin.




Figure 4 Receiver operating characteristic (ROC) curve of E-selectin endothelial microparticle number for prediction of rapid forced expiratory volume in 1 s decline.

influence EMP number, we excluded patients who suffered from these events within a year before and after sample collection. Even after these careful exclusions, however, obscure inflammation may exist and influence the number of circulating EMPs. Furthermore, we could not separate chronic inflammation as a feature of COPD and transit inflammation caused by minor infection or inhalation of air pollutants.

Another limitation is that we did not measure diffusing capacity of the lung for carbon monoxide (DLCO) in this study. DLCO is a useful early marker of capillary injury in smokers.¹⁵ Although current smokers were excluded from the study, it would be interesting to show DLCO values to strengthen the rationale of vascular studies in COPD and give hints to pathogenic mechanisms of endothelial injury in this study. Instead, we accessed the degree of lung destruction using LAA score. There was no correlation between EMP numbers and LAA scores in this study (data not shown), suggesting the small airway disease of COPD might be more relevant to increased EMPs. However, it is well known that the pulmonary capillary bed is significantly reduced in emphysematous regions, and this reduced number of endothelium depresses the circulating EMP numbers. Therefore, we could not discard the possibility of the relationship between increased EMPs and lung destruction.

Circulating EMPs can be repeatedly measured from patients' blood, and the cost of the measurement is quite low. Therefore, EMPs are practical parameters for monitoring the condition of patients with COPD. However, some technical difficulties remain in the measurement of EMPs.³² For example, the sensitivity of detecting EMPs is different among various kinds of FACS machines, and differences in the protocol of the centrifugation also influence results of EMP numbers. In addition, changes in E-selectin EMP numbers in patients with COPD are more rapid than those in other EMPs.⁴ Therefore, time points of withdrawing patients' blood should be fixed. Standardisation of the protocol is essential to perform reliable analyses in a large multicentre study.

In conclusion, we found that high E-selectin EMP numbers under stable conditions predict rapid FEV₁ decline in patients with COPD. Standardising reliable protocol of the EMP enumeration is technically challenging because the size of EMPs is near the detection limit of flow cytometers. However, the E-selectin EMP number sensitively and rapidly reflects changes in disease progression and may be a good biomarker of COPD.

Author affiliations

¹Department of Advanced Preventive Medicine for Infectious Disease, Tohoku University Graduate School of Medicine, Sendai, Japan

²Department of Anaesthesiology, Tohoku University Hospital, Sendai, Japan

³Cellular and Molecular Lung Biology Research Units, Institut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec, Canada

⁴Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Japan

⁵Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan

⁶Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

Contributors TT and HK participated in conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript. SKobayashi and MYanai participated in provision of study material and patients, obtain informed content from the patients and final approval of manuscript. NF, TS, CO, YT, MYamada participated in collection and assembly of data, data analysis and interpretation, and final approval of manuscript. MYamaya, SKurosawa and MYamauchi participated in collection and assembly of data, final approval of manuscript.

Funding This work was supported by a grant from the Japan Society for the Promotion of Science (No. 22390163 and 25293190) to HK.

Competing interests None.

Ethics approval The study was approved by the Ethics Committee of the Japanese Red Cross Ishinomaki Hospital, Japan, and registered at the University Hospital Medical Information Network Clinical Trials Registry (Clinical Trial Number: UMIN000005168).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

1. Vestbo J, Rennard S. Chronic obstructive pulmonary disease biomarker(s) for disease activity needed—urgently. *Am J Respir Crit Care Med* 2010;182:863–4.
2. Barr RG, Mesia-Vela S, Austin JH, *et al*. Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. *Am J Respir Crit Care Med* 2007;176:1200–7.
3. Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. *Eur Respir J* 2007;30:616–22.
4. Takahashi T, Kobayashi S, Fujino N, *et al*. Increased circulating endothelial microparticles in COPD patients: a potential biomarker for COPD exacerbation susceptibility. *Thorax* 2012;67:1067–74.
5. Donaldson GC, Seemungal TA, Bhowmik A, *et al*. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. *Thorax* 2002;57:847–52.
6. Vestbo J, Edwards LD, Scanlon PD, *et al*. Changes in forced expiratory volume in 1 second over time in COPD. *N Engl J Med* 2011;365:1184–92.
7. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV₁ decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. *Am J Respir Crit Care Med* 2001;164:358–64.
8. Calverley PM, Anderson JA, Celli B, *et al*. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* 2007;356:775–89.
9. Diamant M, Tushuizen ME, Sturk A, *et al*. Cellular microparticles: new players in the field of vascular disease? *Eur J Clin Invest* 2004;34:392–401.
10. Freyssonnet JM. Cellular microparticles: what are they bad or good for? *J Thromb Haemost* 2003;1:1655–62.
11. Nozaki T, Sugiyama S, Koga H, *et al*. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. *J Am Coll Cardiol* 2009;54:601–8.
12. Lackner P, Dietmann A, Beer R, *et al*. Cellular microparticles as a marker for cerebral vasospasm in spontaneous subarachnoid hemorrhage. *Stroke* 2010;41:2353–7.
13. Amabile N, Guerin AP, Leroyer A, *et al*. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. *J Am Soc Nephrol* 2005;16:3381–8.
14. Pirro M, Schillaci G, Paltriccio R, *et al*. Increased ratio of CD31+/CD42- microparticles to endothelial progenitors as a novel marker

- of atherosclerosis in hypercholesterolemia. *Arterioscler Thromb Vasc Biol* 2006;26:2530–5.
15. Gordon C, Gudi K, Krause A, *et al.* Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers. *Am J Respir Crit Care Med* 2011;184:224–32.
 16. Amabile N, Heiss C, Chang V, *et al.* Increased CD62e(+) endothelial microparticle levels predict poor outcome in pulmonary hypertension patients. *J Heart Lung Transplant* 2009;28:1081–6.
 17. Lee ST, Chu K, Jung KH, *et al.* Circulating CD62E+ microparticles and cardiovascular outcomes. *PLoS ONE* 2012;7:e35713.
 18. Takahashi T, Kobayashi S, Fujino N, *et al.* Differences in the released endothelial microparticle subtypes between human pulmonary microvascular endothelial cells and aortic endothelial cells in vitro. *Exp Lung Res* 2013;39:155–61.
 19. Jimenez JJ, Jy W, Mauro LM, *et al.* Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. *Thromb Res* 2003;109:175–80.
 20. Thomashow MA, Shimbo D, Parikh MA, *et al.* Endothelial microparticles in mild COPD and emphysema: The MESA COPD Study. *Am J Respir Crit Care Med* 2013;188:60–8.
 21. Kasahara Y, Tudor RM, Taraseviciene-Stewart L, *et al.* Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. *J Clin Invest* 2000;106:1311–19.
 22. Takahashi T, Kobayashi S, Fujino N, *et al.* Relationships between annual changes in FEV1 and numbers of circulating endothelial microparticles in COPD patients. *Am J Respir Crit Care Med* 2013;187:A1525.
 23. Asia Pacific COPD Roundtable Group. Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective. *Respirology* 2005;10:9–17.
 24. Koga H, Sugiyama S, Kugiyama K, *et al.* Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. *J Am Coll Cardiol* 2005;45:1622–30.
 25. Zwicker JI, Trenor CC III, Furie BC, *et al.* Tissue factor-bearing microparticles and thrombus formation. *Arterioscler Thromb Vasc Biol* 2011;31:728–33.
 26. Mostefai HA, Meziani F, Mastronardi ML, *et al.* Circulating microparticles from patients with septic shock exert protective role in vascular function. *Am J Respir Crit Care Med* 2008;178:1148–55.
 27. Miller MR, Hankinson J, Brusasco V, *et al.* Standardisation of spirometry. *Eur Respir J* 2005;26:319–38.
 28. Nishimura M, Makita H, Nagai K, *et al.* Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012;185:44–52.
 29. Goddard PR, Nicholson EM, Laszlo G, *et al.* Computed tomography in pulmonary emphysema. *Clin Radiol* 1982;33:379–87.
 30. Ogura H, Tanaka H, Koh T, *et al.* Enhanced production of endothelial microparticles with increased binding to leukocytes in patients with severe systemic inflammatory response syndrome. *J Trauma* 2004;56:823–30.
 31. Bevilacqua M, Butcher E, Furie B, *et al.* Selectins: a family of adhesion receptors. *Cell* 1991;67:233.
 32. Witwer KW, Buzas EI, Bemis LT, *et al.* Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. *J Extracell Vesicles* 2013;2:20360.